HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO

Ascentage Pharma aims global license agreement with Takeda for Olverembatinib

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas

Lilly's tirzepatide was superior to placebo for MASH resolution

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib

Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Ascentage Pharma’s Phase III study of Olverembatinib cleared by FDA

The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.

Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients